EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Candida and Aspergillus infections in immunocompromised patients: an overview


Reviews of Infectious Diseases 13(3): 487-492
Candida and Aspergillus infections in immunocompromised patients: an overview
Fungal infections in granulocytopenic patients, especially those caused by Candida and Aspergillus spp., and their treatment are discussed.


Accession: 002042481

PMID: 1866554

DOI: 10.1093/clinids/13.3.487



Related references

Systemic infections with Candida sp. and Aspergillus sp. in immunocompromised patients with hematological malignancies: current serological and molecular diagnostic methods. ChemoTherapy 46(3): 219-228, 2000

Current serological and molecular methods in the diagnosis of systemic infections with Candida sp. and Aspergillus sp. in immunocompromised patients with hematological malignancies. Antibiotics and ChemoTherapy 50: 59-68, 2000

Pulmonary resection for invasive Aspergillus infections in immunocompromised patients. Journal of Thoracic and Cardiovascular Surgery 109(6): 1182-96; Discussion 1196-7, 1995

Current strategies in the treatment of invasive Aspergillus infections in immunocompromised patients. Drugs 58(4): 621-631, 1999

Current strategies in the treatment of invasive Aspergillus infections in immunocompromised patients. Drugs 58(4): 621-631, 1999

Fluconazole in localized, deep and disseminated Candida infections in immunocompromised patients. Opportunistic fungal infections: focus on fluconazole Proceedings of an International Symposium held in Lisbon on February 15, 1988: 53-60, 1989

Invasive Candida albicans infections of the oral cavity in immunocompromised patients. Journal of Oral Medicine 41(1): 9-13, 1986

New aspects of infections caused by Aspergillus and Mucor and other filamentous fungi in immunocompromised patients. Revista Clinica Espanola 195(Suppl. 3): 15-25, 1995

Burden of hospitalization of patients with Candida and Aspergillus infections in Australia. International Journal of Infectious Diseases 8(2): 111-120, 2004

The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients. International Journal of Antimicrobial Agents 36(6): 531-536, 2011